Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uma Sinha

Showing results (21-30 of 74) with videos related to

Pageof 8
Sort By:
Pharmacology Research & Perspectives|December 16, 2014
Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritisGreg Coffey, Andreas Betz, Jonathan Graf, et al.
Indian Journal of Endocrinology and Metabolism|June 19, 2013
Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern IndiaUma Sinha, Keshab Sinharay, Sudipta Saha, et al.
The Journal of Biological Chemistry|December 25, 2012
Critical Role for an acidic amino acid region in platelet signaling by the HemITAM (hemi-immunoreceptor tyrosine-based activation motif) containing receptor CLEC-2 (C-type lectin receptor-2)Craig E Hughes, Uma Sinha, Anjali Pandey, et al.
Chemical & Pharmaceutical Bulletin|September 2, 2009
Design, synthesis and discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent factor Xa inhibitorsZhaozhong Jon Jia, Robert Murry Scarborough, Penglie Zhang, et al.
European Heart Journal|March 15, 2013
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)Stuart J Connolly, John Eikelboom, Paul Dorian, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult VolunteersJonathan C Fox, Jennifer L Hellawell, Satish Rao, et al.
Circulation|November 5, 2003
Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosisPatrick André, Thomas LaRocca, Suzanne M Delaney, et al.
Blood|March 30, 2006
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescenceAbhik Datta, Marcia Bellon, Uma Sinha-Datta, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 26, 2014
The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancerGreg Coffey, Andreas Betz, Francis DeGuzman, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 8, 2026
Evaluation of the Current ATTR-CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid FormationStevan Methven Jeknić, Travis A Ahn-Horst, Alan X Ji, et al.
Pageof 8

Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
Pharmacology Research & Perspectives|December 16, 2014
Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritisGreg Coffey, Andreas Betz, Jonathan Graf, et al.
Indian Journal of Endocrinology and Metabolism|June 19, 2013
Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern IndiaUma Sinha, Keshab Sinharay, Sudipta Saha, et al.
The Journal of Biological Chemistry|December 25, 2012
Critical Role for an acidic amino acid region in platelet signaling by the HemITAM (hemi-immunoreceptor tyrosine-based activation motif) containing receptor CLEC-2 (C-type lectin receptor-2)Craig E Hughes, Uma Sinha, Anjali Pandey, et al.
Chemical & Pharmaceutical Bulletin|September 2, 2009
Design, synthesis and discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent factor Xa inhibitorsZhaozhong Jon Jia, Robert Murry Scarborough, Penglie Zhang, et al.
European Heart Journal|March 15, 2013
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)Stuart J Connolly, John Eikelboom, Paul Dorian, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult VolunteersJonathan C Fox, Jennifer L Hellawell, Satish Rao, et al.
Circulation|November 5, 2003
Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosisPatrick André, Thomas LaRocca, Suzanne M Delaney, et al.
Blood|March 30, 2006
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescenceAbhik Datta, Marcia Bellon, Uma Sinha-Datta, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 26, 2014
The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancerGreg Coffey, Andreas Betz, Francis DeGuzman, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 8, 2026
Evaluation of the Current ATTR-CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid FormationStevan Methven Jeknić, Travis A Ahn-Horst, Alan X Ji, et al.
Pageof 8